Use of Human Embryonic Stem Cells in the Treatment of Thrombocytopenia: A Case Series: hESC therapy in Thrombocytopenia


  • Geeta Shroff



Background: Treatment options  such as corticosteroids, immunog- lobulins medicines, blood or platelet transfusions, or splenectomy are used for thrombocytopenia patients. In the present  study, we reported the safety and efficacy of human  embryonic stem cell (hESC) therapy in two patients  with thrombocytopenia. The patients  were presented with general weakness,  and  were  unable to  do  their routine work. After  the  laboratory examinations, it was  confirmed  that  both  the patients were suffering from thrombocytopenia having platelet count 0.70m3 and 0.80m3, respectively.

Methods and Findings: hESCs used in the present  study were ob- tained from a single, spare, expendable, pre-implantation stage fertili- zed ovum taken during natural in vitro fertilization (IVF) and free from immunogenicity. After a single treatment session with hESCs, both patients showed  an increase in blood platelet count and improvement in their condition. No adverse events (AEs) were reported.

Conclusions: hESC therapy  was found  to be safe and effective. The study concluded that hESC therapy improved the condition of patients with thrombocytopenia.